A panelist discusses how detailed clinical assessments of hematologic parameters, symptom burden, thrombotic risk, and molecular markers inform necessary treatment modifications when initial ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line therapy in patients with polycythemia vera (PV) requiring combined phlebotomy ...

Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Canada is at the forefront of addressing global challenges through innovative research. To meet evolving needs, the government is enhancing support and expanding investments to ensure the country ...

The Rockefeller Foundation announced the expansion of Food is Medicine (FIM) solutions for America's Veterans through new pilots in Maryland and New York, in collaboration with the U.S. Department of ...